A citation-based method for searching scientific literature

Elisa F Long, Patricia A Ganz. JAMA Oncol 2015
Times Cited: 23







List of co-cited articles
132 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.
Mary-Claire King, Ephrat Levy-Lahad, Amnon Lahad. JAMA 2014
172
52

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal,[...]. Proc Natl Acad Sci U S A 2014
191
47

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Ranjit Manchanda, Kelly Loggenberg, Saskia Sanderson, Matthew Burnell, Jane Wardle, Sue Gessler, Lucy Side, Nyala Balogun, Rakshit Desai, Ajith Kumar,[...]. J Natl Cancer Inst 2014
102
43

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side,[...]. J Natl Cancer Inst 2014
96
39

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.
Kelly A Metcalfe, Aletta Poll, Robert Royer, Marcia Llacuachaqui, Anna Tulman, Ping Sun, Steven A Narod. J Clin Oncol 2010
109
30


Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
73
21

Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
Matthew B Yurgelun, Elaine Hiller, Judy E Garber. J Clin Oncol 2015
36
17

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
B B Roa, A A Boyd, K Volcik, C S Richards. Nat Genet 1996
543
17

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
17

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
17

Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
Douglas E Levy, Stacey D Byfield, Catherine B Comstock, Judy E Garber, Sapna Syngal, William H Crown, Alexandra E Shields. Genet Med 2011
152
17


Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
William H Parker, Diane Feskanich, Michael S Broder, Eunice Chang, Donna Shoupe, Cynthia M Farquhar, Jonathan S Berek, JoAnn E Manson. Obstet Gynecol 2013
243
17

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
C Oddoux, J P Struewing, C M Clayton, S Neuhausen, L C Brody, M Kaback, B Haas, L Norton, P Borgen, S Jhanwar,[...]. Nat Genet 1996
296
13

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
Robert C Green, Jonathan S Berg, Wayne W Grody, Sarah S Kalia, Bruce R Korf, Christa L Martin, Amy L McGuire, Robert L Nussbaum, Julianne M O'Daniel, Kelly E Ormond,[...]. Genet Med 2013
13

Cost-effectiveness of testing for breast cancer susceptibility genes.
Margaret L Holland, Alissa Huston, Katia Noyes. Value Health 2009
31
13

Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
K A Metcalfe, A Poll, M Llacuachaqui, S Nanda, A Tulman, N Mian, P Sun, S A Narod. Clin Genet 2010
37
13

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
13

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
13

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
625
13

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
13

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
Terri Febbraro, Katina Robison, Jennifer Scalia Wilbur, Jessica Laprise, Amy Bregar, Vrishali Lopes, Robert Legare, Ashley Stuckey. Gynecol Oncol 2015
60
13

Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
C Bethan Powell, Ramey Littell, Elizabeth Hoodfar, Fiona Sinclair, Alice Pressman. Int J Gynecol Cancer 2013
37
13

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Shari Gelber, Lidia Schapira, Steven Come, Virginia F Borges, Bryce Larsen, Judy E Garber, Ann H Partridge. JAMA Oncol 2016
68
13

Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Cecelia A Bellcross, Katherine Kolor, Katrina A B Goddard, Ralph J Coates, Michele Reyes, Muin J Khoury. Am J Prev Med 2011
111
13

Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Janice S Kwon, Angelica M Gutierrez-Barrera, Diana Young, Charlotte C Sun, Molly S Daniels, Karen H Lu, Banu Arun. J Clin Oncol 2010
99
13

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
491
13

Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers.
Brian Drohan, Constance A Roche, James C Cusack, Kevin S Hughes. Ann Surg Oncol 2012
56
13

Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.
Frederick E Dewey, Michael F Murray, John D Overton, Lukas Habegger, Joseph B Leader, Samantha N Fetterolf, Colm O'Dushlaine, Cristopher V Van Hout, Jeffrey Staples, Claudia Gonzaga-Jauregui,[...]. Science 2016
260
13

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Mary B Daly, Robert Pilarski, Michael Berry, Saundra S Buys, Meagan Farmer, Susan Friedman, Judy E Garber, Noah D Kauff, Seema Khan, Catherine Klein,[...]. J Natl Compr Canc Netw 2017
287
13

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
328
13

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
564
13

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Ranjit Manchanda, Shreeya Patel, Antonis C Antoniou, Ephrat Levy-Lahad, Clare Turnbull, D Gareth Evans, John L Hopper, Robert J Macinnis, Usha Menon, Ian Jacobs,[...]. Am J Obstet Gynecol 2017
28
13

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
783
13

Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Lovise Mæhle, Dag Erik Undlien, Jan Norum, Ellen Schlichting. BMC Cancer 2017
31
13

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.
Wendy S Rubinstein, Hongmei Jiang, Lisa Dellefave, Alfred W Rademaker. Genet Med 2009
36
8

Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
Joanne Armstrong, Michele Toscano, Nancy Kotchko, Sue Friedman, Marc D Schwartz, Katherine S Virgo, Kristian Lynch, James E Andrews, Claudia X Aguado Loi, Joseph E Bauer,[...]. JAMA Oncol 2015
78
8

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
8

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
281
8

Opportunities and challenges of next-generation DNA sequencing for breast units.
S M Pilgrim, S J Pain, M D Tischkowitz. Br J Surg 2014
5
40


Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
N D Kauff, P Perez-Segura, M E Robson, L Scheuer, B Siegel, A Schluger, B Rapaport, T S Frank, K Nafa, N A Ellis,[...]. J Med Genet 2002
62
8

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
Kelly A Metcalfe, Nida Mian, Melissa Enmore, Aletta Poll, Marcia Llacuachaqui, Sonia Nanda, Ping Sun, Kevin S Hughes, Steven A Narod. Breast Cancer Res Treat 2012
54
8

Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.
Allison W Kurian, Kerry E Kingham, James M Ford. Curr Opin Obstet Gynecol 2015
24
8



Application of population screening principles to genetic screening for adult-onset conditions.
W Burke, S S Coughlin, N C Lee, D L Weed, M J Khoury. Genet Test 2001
60
8


Public health implications from COGS and potential for risk stratification and screening.
Hilary Burton, Susmita Chowdhury, Tom Dent, Alison Hall, Nora Pashayan, Paul Pharoah. Nat Genet 2013
84
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.